Abstract
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH)
Protein & Peptide Letters
Title: Development of a Mimotope-Based Vaccine Against CD20 Antigen
Volume: 14 Issue: 6
Author(s): Meng Li, Wei Han, Quiyang Zhang, Xiaochang Xue, Zenglu Wang and Yingqi Zhang
Affiliation:
Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH)
Abstract: CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Export Options
About this article
Cite this article as:
Meng Li , Wei Han , Quiyang Zhang , Xiaochang Xue , Zenglu Wang and Yingqi Zhang , Development of a Mimotope-Based Vaccine Against CD20 Antigen, Protein & Peptide Letters 2007; 14 (6) . https://dx.doi.org/10.2174/092986607780989958
DOI https://dx.doi.org/10.2174/092986607780989958 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Current Topics in Medicinal Chemistry Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets From TGF-β to Cancer Therapy
Current Drug Targets Advanced Microfluorescence Methods in Monitoring Intracellular Uptake of “Antisense” Oligonucleotides
Current Organic Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology MicroRNA Functions and Potential Clinical Utility in Glioblastoma
Current Signal Transduction Therapy Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Coexistance of Amyloidosis and Primary Sjögren's Syndrome: An Overview
Current Rheumatology Reviews Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target
Current Pharmaceutical Design Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Platelet Protein Synthesis and Translational Control
Current Proteomics Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews